Tema ETFs LLC Acquires New Shares in Tango Therapeutics, Inc. $TNGX

Tema ETFs LLC acquired a new position in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) during the 2nd quarter, Holdings Channel.com reports. The firm acquired 55,384 shares of the company’s stock, valued at approximately $1,731,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Legal & General Group Plc grew its stake in Tango Therapeutics by 30.7% in the second quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock valued at $36,000 after acquiring an additional 1,640 shares during the period. Russell Investments Group Ltd. raised its position in shares of Tango Therapeutics by 26.7% during the fourth quarter. Russell Investments Group Ltd. now owns 9,794 shares of the company’s stock worth $87,000 after purchasing an additional 2,065 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Tango Therapeutics by 52.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,544 shares of the company’s stock valued at $58,000 after purchasing an additional 2,243 shares in the last quarter. SG Americas Securities LLC lifted its holdings in shares of Tango Therapeutics by 10.2% during the 1st quarter. SG Americas Securities LLC now owns 24,257 shares of the company’s stock valued at $507,000 after purchasing an additional 2,251 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of Tango Therapeutics by 0.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 489,348 shares of the company’s stock valued at $10,237,000 after purchasing an additional 2,272 shares during the period. 78.99% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts have commented on TNGX shares. Raymond James Financial downgraded shares of Tango Therapeutics to a “hold” rating in a report on Thursday, June 25th. HC Wainwright increased their price objective on shares of Tango Therapeutics from $27.00 to $66.00 and gave the stock a “buy” rating in a research report on Tuesday, June 9th. Leerink Partners raised their price objective on shares of Tango Therapeutics from $55.00 to $69.00 and gave the stock an “outperform” rating in a report on Monday, June 8th. Canaccord Genuity Group boosted their price objective on shares of Tango Therapeutics from $42.00 to $46.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Finally, Stifel Nicolaus increased their target price on Tango Therapeutics from $24.00 to $40.00 and gave the stock a “buy” rating in a report on Monday, April 27th. Thirteen equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $43.31.

Tango Therapeutics Stock Performance

NASDAQ TNGX opened at $25.58 on Thursday. Tango Therapeutics, Inc. has a 52 week low of $6.25 and a 52 week high of $34.39. The stock’s 50 day moving average price is $28.74 and its two-hundred day moving average price is $22.12. The stock has a market capitalization of $3.70 billion, a price-to-earnings ratio of -30.09 and a beta of 1.16.

Tango Therapeutics (NASDAQ:TNGX) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.05). On average, equities research analysts forecast that Tango Therapeutics, Inc. will post -1.27 EPS for the current year.

Insider Buying and Selling

In related news, insider Adam Crystal sold 27,000 shares of the firm’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $29.59, for a total value of $798,930.00. Following the completion of the transaction, the insider owned 115,743 shares of the company’s stock, valued at approximately $3,424,835.37. This trade represents a 18.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 6.50% of the company’s stock.

Tango Therapeutics Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.